Multianalyte assay systems in the differential diagnosis of ovarian cancer

Bibliography

• Ries LAG MD, Krapcho M, Stinchcomg DG, SEER Cancer Statistics Review, 1975-2005. National Cancer Institute; Bethesda, MD; 2008
   Google Scholar
• Disaia PJ, Creasman WT. The adnexal mass and early ovarian cancer. In: Clinical Gynecological Oncology. 5th edition. Mosby-Year Book, St. Louis; 1997. p. 253-81
   Google Scholar
• Drake J. Diagnosis and management of the adnexal mass. Am Fam Physician 1998;57:2471-6; 9-80
   PubMed Web of Science ®Google Scholar
• Droegenmueller W. Benign gynecological lesions. In: Mishell DR Jr, editors, Comprehensive Gynecology. 4th edition. Mosby, St. Louis (MO); 2001. p. 479-525
   Google Scholar
• Stany MP, Hamilton CA. Benign disorders of the ovary. Obstet Gynecol Clin North Am 2008;35:271-84, ix
   PubMed Web of Science ®Google Scholar
• Earle CC, Schrag D, Neville BA, Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006;98:172-80
   PubMed Web of Science ®Google Scholar
• Tingulstad S, Skjeldestad FE, Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol 2003;102:499-505
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59
   PubMed Web of Science ®Google Scholar
• Eisenkop SM, Spirtos NM, Montag TW, The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203-9
   PubMed Web of Science ®Google Scholar
• Chan JK, Cheung MK, Husain A, Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006;108:521-8
   PubMed Web of Science ®Google Scholar
• Goodman MT, Howe HL. Descriptive epidemiology of ovarian cancer in the United States, 1992-1997. Cancer 2003;97:2615-30
   PubMed Web of Science ®Google Scholar
• Gostout BS, Brewer MA. Guidelines for referral of the patient with an adnexal mass. Clin Obstet Gynecol 2006;49:448-58
   PubMed Web of Science ®Google Scholar
• Menon U, Gentry-Maharaj A, Hallett R, Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40
   PubMed Web of Science ®Google Scholar
• Risum S, Hogdall C, Loft A, The diagnostic value of PET/CT for primary ovarian cancer–a prospective study. Gynecol Oncol 2007;105:145-9
   PubMed Web of Science ®Google Scholar
• Dearking AC, Aletti GD, McGree ME, How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol 2007;110:841-8
   PubMed Web of Science ®Google Scholar
• Jacobs I, Oram D, Fairbanks J, A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-9
   PubMedGoogle Scholar
• Tingulstad S, Hagen B, Skjeldestad FE, Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996;103:826-31
   PubMedGoogle Scholar
• Tingulstad S, Hagen B, Skjeldestad FE, The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999;93:448-52
   PubMed Web of Science ®Google Scholar
• Bailey J, Tailor A, Naik R, Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases? Int J Gynecol Cancer 2006;16:30-4
   PubMed Web of Science ®Google Scholar
• Enakpene CA, Omigbodun AO, Goecke TW, Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index. J Obstet Gynaecol Res 2009;35:131-8
   PubMed Web of Science ®Google Scholar
• Hakansson F, Hogdall EV, Nedergaard L, Risk of malignancy index (RMI) used as a diagnostic tool in a tertiary centre for patients with a pelvic mass. Acta Obstet gynecol Scand 2012
   PubMed Web of Science ®Google Scholar
• Geomini P, Kruitwagen R, Bremer GL, The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 2009;113:384-94
   PubMed Web of Science ®Google Scholar
• Timmerman D, Testa AC, Bourne T, Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol 2005;23:8794-801
   PubMed Web of Science ®Google Scholar
• Van Holsbeke CD, Van Calster B, Bourne T, External validation of diagnostic models to estimate the risk of malignancy in adnexal masses. Clin Cancer Res 2011;18(3):815-25
   PubMed Web of Science ®Google Scholar
• Hogdall C, Fung ET, Christensen IJ, A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. Gynecol Oncol 2011;123(2):308-13
   PubMed Web of Science ®Google Scholar
• Petri AL, Simonsen AH, Hogdall E, Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. Proteomic Clin Appl 2010;4:304-14
   PubMed Web of Science ®Google Scholar
• Rice GE, Edgell TA, Autelitano DJ. Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer. J Exp Clin Cancer Res 2010;29:62
   PubMed Web of Science ®Google Scholar
• Gorelik E, Landsittel DP, Marrangoni AM, Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:981-7
   PubMed Web of Science ®Google Scholar
• Lambeck AJ, Crijns AP, Leffers N, Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res 2007;13:2385-91
   PubMed Web of Science ®Google Scholar
• Yip P, Chen TH, Seshaiah P, Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. PLoS One 2011;6:e29533
   PubMedGoogle Scholar
• Schaner ME, Ross DT, Ciaravino G, Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003;14:4376-86
   PubMed Web of Science ®Google Scholar
• Moore RG, Brown AK, Miller MC, The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402-8
   PubMed Web of Science ®Google Scholar
• Moore RG, McMeekin DS, Brown AK, A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6
   PubMed Web of Science ®Google Scholar
• Drapkin R, von Horsten HH, Lin Y, Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162-9
   PubMed Web of Science ®Google Scholar
• Huhtinen K, Suvitie P, Hiissa J, Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100:1315-19
   PubMed Web of Science ®Google Scholar
• Nolen B, Velikokhatnaya L, Marrangoni A, Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010;117:440-5
   PubMed Web of Science ®Google Scholar
• Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol 2011;205:358; e1-6
   PubMed Web of Science ®Google Scholar
• Moore RG, Jabre-Raughley M, Brown AK, Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010;203:228; e1-6
   PubMed Web of Science ®Google Scholar
• Van Gorp T, Veldman J, Van Calster B, Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. Eur J Cancer 2012; [Epub ahead of print]
   PubMedGoogle Scholar
• Moore RG, Miller MC, Disilvestro P, Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011;118:280-8
   PubMed Web of Science ®Google Scholar
• Kadija S, Stefanovic A, Jeremic K, The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer 2011;22(2):238-44
   Web of Science ®Google Scholar
• Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev 2010;11:111-16
   PubMed Web of Science ®Google Scholar
• Chang X, Ye X, Dong L, Human Epididymis Protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer 2011;21:852-8
   PubMed Web of Science ®Google Scholar
• Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol 2011;205(4):358e1-6
   Google Scholar
• Kim YM, Whang DH, Park J, Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med 2011;49:527-34
   PubMed Web of Science ®Google Scholar
• Ruggeri G, Bandiera E, Zanotti L, HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta 2011;412:1447-53
   PubMed Web of Science ®Google Scholar
• Van Gorp T, Cadron I, Despierre E, HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer 2011;104:863-70
   PubMed Web of Science ®Google Scholar
• Montagnana M, Danese E, Ruzzenente O, The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011;49:521-5
   PubMed Web of Science ®Google Scholar
• Jacob F, Meier M, Caduff R, No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011;121:487-91
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA news release: FDA clears a test for Ovarian Cancer. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm182057.htm [Accessed 14 May 2010]
   Google Scholar
• Zhang Z, Chan DW. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 2010;19:2995-9
   PubMed Web of Science ®Google Scholar
• Miller R, Smith A, DeSimone CP, Performance of the American college of obstetricians and gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol 2011;117:1298-306
   PubMed Web of Science ®Google Scholar
• Ueland FR, Desimone CP, Seamon LG, Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011;117:1289-97
   PubMed Web of Science ®Google Scholar
• Moore LE, Pfeiffer RM, Zhang Z, Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. Cancer 2012;118:91-100
   PubMed Web of Science ®Google Scholar
• Cramer DW, Bast RC Jr, Berg CD, Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 2011;4:365-74
   PubMed Web of Science ®Google Scholar